INTRODUCTION
============

In recent years, traumatic brain injury (TBI) is not only simple phenomenon confined to damage injured by, but also considered heterogeneous pathological disease state affecting all ages. TBI has a peak incidence between 15-24 years of age[@B10][@B25]. Since it is prevalent in children and young adults, the result of TBI has a serious and devastating effect in social and economic terms[@B23]. Injury grading is very various, range from mild with low mortality rate to severe with life-threatening lesion. The mainstay treatment for TBI is to reduce the extent of secondary brain damage after the primary insult[@B23].

Prediction of the severity and prognosis in TBI is currently based on demographic, clinical and radiological features, including age, initial Glasgow Coma Scale (GCS) score, pupillary response, vital signs, significant non-cranial injuries, and computed tomography (CT) indices. The clinical outcome prediction by those informations have several limitations because neurologic assessment is often performed not exactly by the use of many drugs (analgesics, sedatives, neuromuscular blocking agent, etc.) and sometimes, discrepancy exists when compared initial radiological information with clinical course, especially in diffuse injury without focal mass lesion. Therefore, there is enormous diagnostic and prognostic promise in developing assays that measure TBI-associated biomarkers accurately and specifically[@B36].

A biomarker is an indicator of a specific biological or disease state that can be measured using samples taken from either the affected tissue or peripheral body fluids. In other organ disease and injury, the specific-markers that have proven invaluable are actively applicated in clinical field as rapid diagnostic tools. But in TBI, there is no such definitive biomarker. Previously investigated markers in large studies include neuron-specific enolase (NSE)[@B27][@B33], myelin basic protein[@B5][@B33], glial protein S-100 beta (S100B)[@B18][@B24][@B31], glial fibrillary acidic protein (GFAP)[@B16]. Recently, as a result of increased development of proteomics analysis and other discovery techniques, investigators have reported ubiquitin C-terminal hydrolase-L1 (UCH-L1), neuron specific and concentrated in neuronal soma, as a novel potential marker for brain injury[@B13].

We investigated the levels of S100B, GFAP, and UCH-L1 in peripheral blood, and would determine the predictive value of the serum level of these markers for clinical outcomes after TBI. In addition, we hypothesized that the combination analysis of neuronal cell body marker (UCH-L1) and glial markers (S100B, GFAP) could reflect different pathophysiology would be more informative than either biomarker alone or only glial and neuronal same category markers investigation.

MATERIALS AND METHODS
=====================

From July on 2013 to August on 2014, we investigated 45 patients with TBI. On admission, CT scans were performed in all patients. The following variables were recorded for each of the patients; age, sex, a history of specific diseases, kind of trauma, the time of hospital admission, radiologic findings, initial GCS score, status of pupils, treatment modality, and GCS score at discharge. The patients were classified into two groups according to clinical manifestations.

1\) The group A, termed the \"severe injured group\", consisted of those who had GCS score under 6 on admission

2\) The group B, consisted of those who had GCS score of 13 to 15 on admission

In all enrolled patients, initial blood sampling was performed within 24 hours after trauma. The routine blood examinations were performed via peripheral veins. The first blood sample was obtained within 4 hours arrival on hospital. We investigated three makers in this study : 2 glial markers (S100B, GFAP) and 1 neuronal maker (UCH-L1).

Biomarker identification
------------------------

To determine the level of S100B, GFAP, UCH-L1 protein, blood samples were centrifuged, separated and serum was stored at -50℃ until the analysis, and once gathered, serum samples from all patients were analyzed by sandwich enzyme-linked immunosorbent assay (ELISA) to S100B, GFAP, and UCH-L1 with a high degree of sensitivity using a commercially available kit. Monoclonal antibody specific for S100B has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any S100B present is bound by the immobilized antibody. A biotinylated polyclonal antibody specific for S100B is added to the wells. Following a wash to remove any unbound reagent, an enzyme complex is added to the wells. After incubation and washing, a substrate solution is added to the wells. The GFAP ELISA utilized a proprietary mouse monoclonal antibody for solid phase immobilization and a proprietary polyclonal rabbit antibody for detection. The antibodies detect both whole GFAP molecules as well as GFAP breakdown products, potentially resulting in a more complete measure of GFAP levels in circulation[@B36]. The UCH-L1 was assayed using a sandwich ELISA as previously described[@B22]. Reaction wells were coated with mouse monoclonal antibody, capture antibody in 0.1 M sodium bicarbonate, pH 9 and incubated overnight at 4℃. Plates were then emptied out and blocking buffer was added and incubated for 30 minutes at ambient temperature with gentle shaking. This was followed by addition of antigen standard. The plate was incubated for two hours at room temperature then washed using an automatic plate washer. Rabbit polyclonal antibody, detection antibody in blocking buffer was then added to wells at 100 µL/well and the plates were further incubated for 1.5 hours at room temperature. After additional automatic washing, biotinyl-tyramide solution was added and the plate was incubated for 15 minutes at room temperature followed by automatic washing. Addition of streptavidin-horseradish peroxidase (1 : 500, 100 uL/well) and 1% bovine serum albumin for 30 minutes incubation at room temperature was followed by automatic washing. Finally, the wells were developed with substrate solution : Ultra-Trail du Mont-Blanc ELISA (100 uL/well) with incubation for 5 to 30 minutes and read at 652 nm with spectrophotometer.

We compared serum levels of S100B, GFAP, and UCH-L1 in severe (GCS score\<6) and mild injured group (GCS score 13 to 15) at each of the admission time. Acute injury severity was functionally assessed by the GCS score on admission. If there was difference in GCS score between admission and a few hours after hospitalization, the 24-hour post injury GCS score was used as an end point because the GCS score of a few patients was confused by other factors, including the presence of alcohol, analgesics, sedatives in the first several hours after injury. We also compared biomarker levels according to CT findings reveal parenchymal injury or not. Clinical outcome after acute injury was assessed by the Glasgow Outcome Scale score at 3 months after TBI.

The Mann-Whitney test was used to determine the difference of biomarker serum level between both groups in glial and neuronal proteins. In all investigated cases, statistical significance was established in *p*\<0.05. Spearman rank correlation test was used to test correlations between quantitative variables for significance. The receiver operator characteristics (ROC) curve was used to assess the extent to which the S100B, GFAP, and UCH-L1 levels differed between both groups with good recovery after minor injury. The ROC curve was obtained by calculating the sensitivity and specificity for every distinct observed data value, and plotting sensitivity against 1-specificity. Diagnostic accuracy was assessed by the area under the curve (AUC). This area represents the probability that a person, with disability after head injury has a higher S100B, GFAP, and UCH-L1 level than head injured person without disability. The ROC curve was used to determine cutoff value that insured a high proportion of patients with poor outcomes after TBI would be detected (high sensitivity) at the cost of a relatively high false positive rate (low specificity). Analysis was performed using the Statistical Package for Social Sciences (SPSS 11 for windows; SPSS Inc., Chicago, IL, USA).

RESULTS
=======

The demographic characteristics and neurologic data are summarized as follows ([Table 1](#T1){ref-type="table"}). In 45 patients that were enrolled in this study, 33 patients were male and 12 patients were female. The mean age was 58.5 years, ranged from 19 to 84. The patients were classified into two groups. The group A included 14 patients, and the group B included 31 patients.

The mean initial GCS score was 5.3 and 14.5 in group A and B. In the CT scan, the parenchymal injury was shown in 20 patients and 25 patients had non parenchymal injury. The patients with severe TBI had significantly elevated serum concentration of S100B, GFAP, and UCH-L1 after injury compared with minor injured group. As expected, S100B and GFAP showed inverse correlation between GCS score and serum level, but there was no such pattern in UCH-L1. The UCH-L1 frequently was not detected in minor injured group. Although detected in minor injured group, the concentration of serum level was ranged from 0.07 to 1.45 ng/mL. In severe injured group, the concentration was ranged from 0.96 to 151.25 ng/mL. Minor injured patients had relatively very low serum concentration compared to severe group ([Fig. 1](#F1){ref-type="fig"}). Four patients were dead during hospitalization and the others had poor clinical outcome in severe injured patients (group A, n=14). All of minor injured patients (group B, n=31) had good clinical course ([Table 2](#T2){ref-type="table"}). The median serum concentrations of markers taken at the time of hospital admission in patients with severe TBI were raised 5.1 fold for S100B, 5.5 fold for GFAP, and 439.1 fold for UCH-L1 compared to the mild injury group. Furthermore, the median serum S100B, GFAP, and UCH-L1 concentration were higher in patients who were dead compared to survival patients post TBI. The increasing ratio of serum concentration was similar in S100B and GFAP, but in UCH-L1, there was enormous difference between severe and mild injured group. The statistical significant elevation of each markers was found in severe injured and dead patients (*p*\<0.001; Mann-Whitney test [Table 3](#T3){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}; [Table 4](#T4){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}). It suggests S100B, GFAP, and UCH-L1 can be significant predictor for severity and clinical outcome in TBI. The patients who had parenchymal injury on CT scan had higher serum concentrations of S100B, GFAP, and UCH-L1 than the patients without parenchymal injury. Similarly, when analyzed within each group, the patient with parenchymal injury on CT scan was higher than non injured group ([Table 5](#T5){ref-type="table"}). The correlation between the brain specific markers and clinical indices, demographic characteristics and neurologic data were as follows ([Table 6](#T6){ref-type="table"}). The brain specific proteins were seems to be mildly inter-correlated with demographic characteristics. Age and sex were not shown significant correlation to any markers. The statistical significant correlation was presented between initial GCS score reflecting injury severity and all markers (*p*\<0.01). Only GFAP had significant correlation parenchymal injury on CT scan, not to S100B and UCH-L1 (*p*\<0.01). Because GFAP is specific glial protein as compared with neuronal specific UCH-L1, it more reflect to general damage to direct injury. In analysis of each markers, glial proteins (S100B and GFAP) were significantly correlated with each other. But there is no statistical significant correlation between glial (S100B and GFAP) and neuronal marker (UCH-L1) ([Fig. 4](#F4){ref-type="fig"}).

The ROC curves of the S100B, GFAP, and UCH-L1 was created to explore the ability sensitivity and specificity of prediction of poor outcome ([Fig. 5](#F5){ref-type="fig"}). The AUC was 0.95 for S100B, 0.99 for GFAP, and 0.88 for UCH-L1. The figure clearly shows higher AUC for S100B, GFAP, and UCH-L1. The result of this definite curve might be influence from the relatively small number of patients enrolled in this study and exclusion of moderate injured patients. The cutoff values were established 27.01, 18.00, and 0.96 ng/mL in S100B, GFAP, and UCH-L1 as the best operating point. To predict of poor outcomes by these values, high prediction rate was achieved ([Table 7](#T7){ref-type="table"}). The sensitivity and specificity of this cutoff value for poor outcome is 92%, 87% in S100B, 92%, 93% in GFAP, and 78%, 96% in UCH-L1.

DISCUSSION
==========

A biomarker is a biological indicator of a specific or pathological state. Molecular biomarkers can take many forms and, as a consequence, a variety of strategies have been undertaken for their discovery, including transcriptional, proteomic, and metabolomic profiling. Molecular markers have been detected in tissue samples or body fluids. For example, the release patterns the MB isozyme of creatine kinase (CK-MB, predominantly found in cardiac muscle) following myocardial infarction provides information related to the size of the infarction, the effect of treatment, and the prognosis of the patient[@B9]. Troponin levels have also become a standard biomarker used in the diagnosis and determination of treatment for myocardial infarction[@B1][@B14]. The identification pathology-specific biomarkers can assist in the diagnosis and estimation of prognosis, and can serve as surrogate markers for monitoring the effectiveness of a treatment. Our prospective observational study in 45 patients with severe or mild TBI demonstrates that prediction of severity of brain damage and clinical outcome after TBI may be improved with the determination of serum level of brain specific proteins (S100B, GFAP, and UCH-L1) at the time of hospital admission. The analysis of brains specific proteins S100B, GFAP, and UCH-L1 together with GCS score can be used best predictive tool for severity and outcome in TBI patients. Our data is in line with previous study that showed a correlation of S100B, GFAP, and UCH-L1 with mortality after severe TBI[@B7][@B26][@B33]. The S100B and NSE serum concentration were higher in the first hours post injury in patients with poor compared to good outcome[@B19][@B32]. The relevance of the determination of S100B protein in serum is not only restricted to severe TBI. After minor head injury raised S100B serum levels within 12 hours post injury predict neuropsychological dysfunction on measures of reaction time, attention, and speed of information processing after 12 months[@B3].

The cerebral origin of S100B in peripheral blood is not always obvious. S100B is expressed not only in brain tissue but also in white and brown fat, skin, and skeletal muscle tissue (in much lower concentrations than in the brain[@B29][@B35]). Increased serum S100B levels after heart surgery have been shown to be at least partly of extra-cerebral origin, probably as a result of surgically traumatized fat, muscle and bone marrow. Also, in multi-trauma patients, extra-cerebral S100B may contribute to the measured serum level[@B2]. The uncertainty in the cerebral or extracerebral origin of serum S100B probably does not exist for GFAP and UCH-L1. GFAP is an intermediate filament monomer found only in the cytoskeleton of astroglial cells, and thus is specific for the central nervous system (CNS). Therefore it is likely that serum GFAP is entirely derived from the brain. UCH-L1, also known as neuronal specific gene product 9.5, is the most strongly associated with the CNS, where it is predominantly detectable in neuronal cell bodies.

Previous studies have identified inflammatory response molecules, excitotoxic amino acids, oxidative stress markers, and enzymes in cerebrospinal fluid (CSF)[@B4][@B8][@B11][@B17][@B21][@B34]. But measurement of CSF biomarkers requires placement of ventricular catheters, which may influence CSF protein levels[@B6][@B15] and may leading to complication such as infection. If it is possible to extract biomarkers from peripheral blood, more convenient access to study with low complication will be achieved. The UCH-L1 level was also examined in only CSF as a biomarker of severe TBI[@B12][@B28]. Siman et al.[@B30], also reported an elevation of UCH-L1 signals, among a panel of other putative markers, in CSF of severe TBI patients. Mondello et al.[@B20], were the first to systematically assess UCH-L1 in human serum after TBI and to compare levels with those found in CSF of the same patients. They confirmed that UCH-L1 protein is present in human serum and that its levels are significantly elevated after severe TBI using ELISA analysis. Additionally, UCH-L1 was detectable in blood very early after injury, related to injury magnitude and may be an early predictor of clinical outcome. In our study, not all, UCH-L1 was detected in serum of mainly severe injured group and levels of UCH-L1 were significantly elevated in serum from severe injured subjects compared to mild group. This result maybe imply that because UCH-L1 is very specific proteins reflecting neuronal cell body injury, although the astrocyte or other glial component were damaged, if damage of neuronal cell body was not severe, significant value is not detected. For this reason, the polarization might be seen in scatter plot of UCH-L1. The pathophysiology pattern could be various in TBI. Although glial tissue damage exists, the neuronal cell body always is not damaged in TBI and less vulnerable to injury than glial cells. Glial cells are more affected to injury than neuronal cell and according to severity of injury, damage patterns could be difference. Though the biomarkers were investigated in past, single marker, only each glial markers, glial and neuronal marker reflecting axonal injury, not neuronal cell body marker were analyzed[@B29][@B35]. For this reason, multi-markers analysis that presents glial and neuronal cell body damage should be performed. A single biomarker or same category markers may not have the desired level of sensitivity and required specificity for diagnostic purposes. Thus, comprehensive analysis of variable makers, glial and neuronal proteins, will be provide more precise and sensitivity clinical utility.

Our study does not shown a significant correlation between serum brain specific protein level and the other demographic characteristics except hospital admission GCS score and parenchymal injury on radiologic examination. In previous study of correlation of S100B or NSE with GCS score, positive correlation was found[@B19]. Some authors[@B32][@B33], reported there was no significant correlation between serum brain specific protein level and GCS score. The absence of correlation may be due to the fact that consciousness is often iatrogenically lowered when patients are intubated at the trauma scene with the use of anesthetics, sedative drugs, and neuromuscular blockade agents. One of the clinical implications of the current study may be that in patients in whom the GCS score cannot be reliably obtained in emergency department, blood specific protein levels in blood may be a good indicators for the severity of the brain damage. In parenchymal injury, direct neuronal and/or glial injury like contusion, may contribute to increase serum biomarker than focal mass lesion, pressure effect such as subdural or epidural hemorrhage. The pattern of brain injury is associated to difference elevation of markers. According to this result, better outcome may can be expected in mass effect without high level of markers than with high elevation.

In result of the correlations, there was no significant correlation between glial and neuronal cell body marker. The brain consists of many elements such as neuronal cell body, axon, Schwann cell, glial cells, and CSF. According to the mechanism and severity of injury, various damage patterns are presented. Glial makers (S100B, GFAP) of each other belong to similar category but UCH-L1 is different. The glial cells damage is not certainly matched to neuronal cell damage (i.e., focal mass lesion versus diffuse injury). Different patterns of biomarker release imply that different patterns of structural damage involve different pathophysiological mechanisms and may require different therapeutic approaches. Because the S100B, GFAP, and UCH-L1 could not shows significant correlation to each other, multi-marker combined analysis reflecting different pathophysiology of each other is needed to predict for severity and clinical outcome.

Although these data showed encouraging result for prediction of severity of brain damage and clinical outcome, we recognize that there are limitations to this study. First, this study were performed in limited number of patients. Second, this study did not establish control group, and only compared with severe group and mild group. Thus, there are stratification errors, and the applicability of this result to patients is not definitive. Further study with larger cases and adequate control groups is required to assess the clinical application of these results.

CONCLUSION
==========

The serum level of glial and neuronal biomarkers (S100B, GFAP, UCH-L1) at the time of admission were significantly correlated with clinical outcome after TBI and have reasonable sensitivity and specificity for determinating of severity and predicting important clinical outcomes. The identification of these markers would have clinically significant implications, including the diagnosis, prognosis and optimal treatment. The brain consists of many elements, not simple components. According to the mechanism and severity of injury, various damage patterns and different pathophysiology are presented. Hence, in clinical application of biomarkers, serum based combined multi-marker analysis reflecting glial and neuronal cell damage should be considered for understanding more precise pathophysiological state of brain and different therapeutic approaches.
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###### Demographic characteristics and neurologic state on admission
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GCS : Glasgow Coma Scale

###### Clinical outcomes after traumatic brain injury
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Good outcomes : Glasgow Outcome Scale (GOS) 4-5, Poor outcome : GOS 1-3

###### Mean serum concentrations of biomarkers in each groups (severe/mild injured)
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^\*^*p*\<0.001 (*p* values of the Mann-Whitney test for differences between each groups). S100B : S-100 beta, GFAP : glial fibrillary acidic protein, UCH-L1 : ubiquitin C-terminal hydrolase-L1

###### Mean serum concentration of biomarkers in each groups (death/survivor)
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^\*^*p*\<0.001. S100B : S-100 beta, GFAP : glial fibrillary acidic protein, UCH-L1 : ubiquitin C-terminal hydrolase-L1

###### Mean serum concentrations of biomarkers according to parenchymal injury on radiologic examination
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PI : Parenchymal injury, S100B : S-100 beta, GFAP : glial fibrillary acidic protein, UCH-L1 : ubiquitin C-terminal hydrolase-L1

###### Spearman correlation coefficient between serum concentrations and clinical variables
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^\*^*p*\<0.01. S100B : S-100 beta, GFAP : glial fibrillary acidic protein, UCH-L1 : ubiquitin C-terminal hydrolase-L1, GCS : Glasgow Coma Scale, PI : parenchymal injury

###### Detection rate of poor outcomes by cutoff values
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S100B : S-100 beta, GFAP : glial fibrillary acidic protein, UCH-L1 : ubiquitin C-terminal hydrolase-L1
